https://orcid.org/0000-0002-9407-3395
References
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477.
- Brunton LL, Lazo JS, Parker KL, et al. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th. McGraw-Hill; 2006. p. 461–500.
- Zanda MT, Fattore L. Addictive substances and neurological disease. Alcohol, tobacco, caffeine, and drugs of abuse in everyday lifestyles, chapter 29 – novel psychoactive substances: a new behavioral and mental health threat, 2017; 341–353.
- Wikström M, Holmgren P, Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol. 2004 Jan-Feb;28(1):67–70.
- McCann UD, Eligulashvili V, Mertl M, et al. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology (Berl). 1999;147(1):56–65.
- Garratt AM, Hutchinson A, Russell I. Network for evidence-based practice in northern and Yorkshire (NEBPINY). The UK version of the Seattle Angina questionnaire (SAQ-UK): reliability, validity and responsiveness. J Clin Epidemiol. 2001 Sep;54(9):907–915.
- Kutlu R, Memetoğlu ME, Myrataliev MT. Comparison of the safety and efficacy of ivabradine, nebivolol, trimetazidine and ranolazine therapies in the treatment of stable angina pectoris patients with left ventricular dysfunction. Turkiye Klinikleri J Cardiovasc Sci. 2016;28(2):49–60.
- Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13:227–236.
- Spielberger CD, Gorsuch RL, Lushene RE. Test manual for the state trait anxiety inventory. 1 st ed ed. California: Consulting Psychologists Press; 1970.
- Abdel-Salam OME, El-Batran S. Pharmacological investigation of trimetazidine in models of inflammation, pain and gastric injury in rodents. Pharmacology. 2005 Nov;75(3):122–132.
- Serarslan Y, Bal R, Altug ME, et al. Effects of trimetazidine on crush injury of the sciatic nerve in rats: a biochemical and stereological study. Brain Res. 2009;1247:11–20.
- Liu M, Wei W, Stone CR, et al. Beneficial effects of trimetazidine on expression of serotonin and serotonin transporter in rats with myocardial infarction and depression. Neuropsychiatr Dis Treat. 2018;14:787–797.
- Hirakawa R, El-Bizri N, Shryock JC, et al. Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine. Neuropharmacology. 2012;62(7):2251–2260.
- Gould HJ. 3rd. J Neurol Sci. 2016;369:310–311.
- Gould HJ 3rd, Garrett C, Donahue RR, et al. Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol. 2009 Dec;20(8):755–758.
- Kwon L, Rosendorff C. The medical treatment of stable angina. Chronic Coronary Artery Dis. 2018;20:280–302.
- Akan BD, Ozkay UD. The antinociceptive effects of some piperazine alkanol derivatives. Cukurova Med J. 2019;44(3):729–744.
- Chen Y, Wang G, Xu X, et al. Design, synthesis and biological activity evaluation of arylpiperazine derivatives for the treatment of neuropathic pain. Molecules. 2011;16:5785–5806.
- Chae E, Yi H, Choi Y, et al. Synthesis and pharmacological evaluation of carbamic acid 1-phenyl-3-(4-phenyl-piperazine-1-yl)-propyl ester derivatives as new analgesic agents. Bioorg Med Chem Lett. 2012;22:2434–2439.
- Wild KD, McCormick J, Bilsky EJ, et al. Antinociceptive actions of BW373U86 in the mouse. J Pharmacol Exp Ther. 1993;267:858–865.
- Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–316.
- Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther. 2010;27:193–201.
- Casey GP, Roberts JS, Paul D, et al. 3rd. Ranolazine attenuation of CFA-induced mechanical hyperalgesia. Pain Med. 2010;11(1):119–126.
- Gould HJ 3rd, Soignier RD, Cho SR, et al. Ranolazine attenuates mechanical allodynia associated with demyelination injury. Pain Med. 2014;15(10):1771–1780.
- European Medicines Agency Evaluation of Medicines for Human Use, European Medicines Agency, 2008. International nonproprietary name: ranolazine procedure No. EMEA/H/C/805.
- Adverse Drug ISMP. Reactions. Hosp Pharm. 2013;48(5):360–365.
- Tolunay H. Does ranolazine reduce pain perception with cerebral effect? Clin Ther. 2020;42(2):374–375.